Rockwell Medical, INC 8-K filings

Rockwell Medical, Inc. has released an updated corporate presentation on August 13, 2026, providing a general overview of its business and strategic positioning.

Rockwell Medical announced second quarter 2026 results, highlighting an 11% increase in net sales to $17.8 million, improved gross margins to 18%, and positive cash flow from operations.

Rockwell Medical announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Rockwell Medical, Inc. announced a one-for-ten reverse stock split of its common stock, effective July 1, 2026, to adjust its outstanding shares.

Rockwell Medical, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, advisory vote on executive compensation, ratification of auditors, and approval of a reverse stock split.

Rockwell Medical has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Rockwell Medical, Inc. has released an updated corporate presentation on May 7, 2026, detailing its current business status and strategic direction.

Rockwell Medical reported $17.3 million in net sales and $2.9 million in gross profit for Q1 2026, announcing operational changes expected to boost annualized gross profit by over $3 million.

Rockwell Medical, Inc. announced the availability of an updated corporate presentation on March 26, 2026.

Rockwell Medical announced its fourth quarter and full-year 2025 financial results, highlighting significant gross margin improvement in Q4 and positive operating cash flow, despite a full-year revenue decline.

Rockwell Medical announced preliminary unaudited financial results for Q4 and full-year 2025, showing increased revenue, positive cash flow, and improved gross margin.

Rockwell Medical, Inc. announced a one-year extension of its product purchase agreement with DaVita, Inc. through December 31, 2026, which also includes a price increase on products.

Rockwell Medical, Inc. announced the immediate resignation of Andrea Heslin Smiley from its Board of Directors and the appointment of Joseph H. Dawson as a new Class II director.

Rockwell Medical, Inc. announced the availability of an updated corporate presentation on November 12, 2025.

Rockwell Medical, Inc. announced its third quarter 2025 financial results, reporting $15.9 million in net sales and achieving Adjusted EBITDA profitability, while reiterating its full-year 2025 guidance.

Rockwell Medical, Inc. announced the immediate appointment of Heather Hunter as its Senior Vice President and Chief Operating Officer, effective September 23, 2025.

Rockwell Medical reports a significant sales decline in Q2 2025 due to a major customer transition, but improved cash flow and secured new contracts.

Rockwell Medical's 2025 Annual Meeting saw the election of directors, approval of executive compensation, ratification of the accounting firm, and an increase in shares reserved for the long-term incentive plan.

Rockwell Medical, Inc. released an updated corporate presentation on May 12, 2025.

Rockwell Medical announced a 17% decrease in net sales for Q1 2025, but maintained gross profit levels and improved gross margin.

Rockwell Medical, Inc. released an updated corporate presentation on March 20, 2025.

Rockwell Medical reports its first profitable year on an adjusted EBITDA basis, alongside record net sales and gross profit for 2024, but anticipates a revenue decline in 2025 due to a major customer transition.

Rockwell Medical, Inc. has appointed Jesse Neri as Senior Vice President and Chief Financial Officer, effective immediately.

Rockwell Medical has filed a prospectus supplement for a potential offering of up to $25 million of its common stock.

Rockwell Medical, Inc. released an updated corporate presentation on November 12, 2024.

Rockwell Medical reports a profitable third quarter of 2024, driven by increased sales and improved margins.

Rockwell Medical, Inc. released an updated corporate presentation on August 8, 2024, providing insights into the company's current status and future plans.

Rockwell Medical reports a profitable second quarter of 2024 on a cash flow and adjusted EBITDA basis, driven by a 43% increase in net sales compared to the same period last year.

Rockwell Medical and Evoqua Water Technologies have amended their asset purchase agreement, resulting in an extended payment schedule and a partial reduction of deferred payments for Rockwell.

Rockwell Medical's 2024 Annual Meeting saw the election of two Class III directors, approval of executive compensation, and ratification of the company's auditor.